FDA Approves FOSAPREPITANT DIMEGLUMINE — Eugia US LLC

The FDA has granted tentative approval to fosaprepitant dimeglumine, an intravenous antiemetic, enabling Eugia US LLC to enter the market pending final resolution of a patent dispute. This approval provides the manufacturer with a near-term commercial opportunity in the acute chemotherapy support sector while patent litigation proceedings play out.